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Objective: A simple and reproducible large animal model of dilated cardio-
myopathy has yet to be developed. This study was performed to establish a
canine model of dilated cardiomyopathy. Methods: Six closed-chest pure-
bred beagles weighing 8 to 12 kg (10 6 1.9 kg) underwent intracoronary
infusion of doxorubicin (Adriamycin). Low-dose (0.7 mg/kg) doxorubicin
was infused into the left main coronary artery through a 5F Judkins
catheter. Infusions were repeated weekly for 5 weeks. We evaluated the
effects on cardiac hemodynamics, chamber size, the neuroendocrine system,
and cardiac ultrastructure before and 1 and 3 months after five intracoro-
nary infusions of doxorubicin. Results: Three months after treatment,
fractional shortening (mean 6 standard error of the mean) had decreased
from 36.5% 6 0.8% to 21.7% 6 1.4% (p 5 0.0003), and left ventricular
ejection fraction had decreased from 71.0% 6 3.3% to 36.3% 6 5.5% (p 5
0.001). The left ventricular diastolic dimension had increased from 27.8 6
0.9 to 35.5 6 0.6 mm (p 5 0.003), and the left ventricular end-diastolic
volume had increased from 27.5 6 1.8 to 38.3 6 1.9 ml (p 5 0.015). Left
ventricular end-diastolic pressure had increased from 8.5 6 0.9 to 14.5 6
1.1 mm Hg (p 5 0.01), and the stroke volume had decreased from 16.7 6 0.9
to 11.5 6 0.4 ml (p 5 0.001). During the same period, the plasma
norepinephrine concentration also increased from 114 6 27.4 to 423 6 88.9
pg/ml (p 5 0.024), and plasma atrial natriuretic peptide levels increased
from 33.8 6 7.0 to 76.5 6 14.8 pg/ml (p 5 0.012). Histologic changes such
as myofiber atrophy and cytoplasmic vacuolation, accompanied with inter-
stitial fibrosis, were found predominantly in the left ventricle. Conclusion:
Repeated intracoronary infusions of doxorubicin represent a simple and
reliable technique to produce dilated cardiomyopathy in the dog. This
model can be used to evaluate the effects of new therapies, especially
surgical treatments such as dynamic cardiomyoplasty and reduction ven-
triculoplasty, on dilated cardiomyopathy. (J Thorac Cardiovasc Surg 1998;
115:1367-73)
Heart failure is a syndrome of associated abnor-mal physiologic characteristics that include left
ventricular dysfunction and dilation, activation of
the neuroendocrine system, and restriction of phys-
ical activity. The progression of these characteristics
during the evolution of heart failure has been diffi-
cult to determine in human beings because of the
uncertainty of when heart failure in fact begins or
the effects of age, concomitant diseases, and medi-
cations. Because of these problems, animal models
of chronic heart failure are important in evaluating
the effects of new therapies for heart failure. Many
methods to produce a heart failure model have been
reported in various animal species.1-5 However, it is
difficult to measure cardiac hemodynamics accu-
rately in small animals.
In the clinical setting, end-stage left ventricular
failure caused by cardiomyopathy can now be
treated with heart transplantation, cardiomyoplas-
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ty,6 or reduction ventriculoplasty.7 Research thus
should be performed in an animal model of cardio-
myopathy. However, the experimental evaluation of
these new therapies has been hampered because a
stable and reproducible large animal model of
chronic heart failure is still lacking. Especially, a
model of dilated cardiomyopathy has never been
established. Previous efforts to create chronic heart
failure in large animals required complex surgical
procedures.8-10 If we want to assess the effects of
surgical treatments like transplantation, cardiomyo-
plasty, or ventriculoplasty, a large animal model of
nonreversible heart failure not requiring complex
thoracic procedures such as thoracotomy or pericar-
diotomy would be the most appropriate. The pur-
pose of this study was to establish a simple and
reproducible model of dilated cardiomyopathy in
closed-chest beagles.
Materials and methods
Nine purebred adult beagles weighing 8 to 11 kg were
used for the study. All animals were kept in clean cages
and were provided with regular food and sterile water.
They received humane care in compliance with the “Prin-
ciples of Laboratory Animal Care” formulated by the
Institute of Laboratory Animal Resources and the “Guide
for the Care and Use of Laboratory Animals” published
by the National Institutes of Health (NIH Publication No.
86-23, revised 1985). The protocol was approved by the
Kobe University School of Medicine Experimental Ani-
mals Committee.
Hemodynamic evaluation. For each hemodynamic
measurement, the beagles were anesthetized with sodium
pentobarbital (25 mg/kg, intravenously) and permitted to
breathe spontaneously. Echocardiography, cardiac cathe-
terization, and left ventriculography were performed be-
fore the treatment and 1 and 3 months after the last
intracoronary injection of doxorubicin (Adriamycin). All
echocardiograms were performed with the dog lying in the
left decubitus position. Left ventricular echocardiograms
were obtained at the chordal level just below the tips of
the mitral leaflets with an echocardiograph (SSH-140A,
Tohshiba Medical Inc., Tokyo, Japan). All cardiac cath-
eterizations were performed under sterile conditions. A
7.5F Swan-Ganz catheter (Baxter Healthcare Corp., Ir-
vine, Calif.) was advanced from the femoral vein to the
pulmonary artery and a 4F pigtail catheter from the
femoral artery to the left ventricle for pressure measure-
ment. Arterial and intracardiac pressures were measured
with a polygraph (363, NEC San-ei Instruments, Ltd.) and
recorded (8M14, NEC San-ei Instruments Ltd.). Cardiac
output was measured by the thermodilution technique
and was based on the mean of at least five measurements
recorded by a cardiac output computer. Left ventriculo-
grams were obtained during each catheterization imme-
diately after completion of the hemodynamic measure-
ments with the dog placed on its right side. Left
ventriculograms were recorded on videotape and analyzed
with a Cardio 500 device (Kontron Elektronik GmbH).
Correction for image magnification was made with a
calibrated grid placed at the level of the left ventricle. Left
ventricular volumes were measured by the area-length
method.11
Intracoronary doxorubicin. Intracoronary infusions
were performed with a catheter. Under pentobarbital
anesthesia (25 mg/kg, intravenously), a 5F Judkins cathe-
ter was inserted into the left main coronary artery with the
aid of a fluoroscope through a 5F sheath placed in the
femoral artery. Doxorubicin was infused at a rate of 0.7
mg/kg in six beagles. The doxorubicin was dissolved in 20
ml of 0.9% sodium chloride and delivered by bolus
injection into the coronary artery. Infusions were repeated
each week for a total of 5 weeks. This protocol was
established during preliminary studies in six beagles in
which the dose of doxorubicin was adjusted to prevent
immediate lethal myocardial injury. At preliminary study
beagles with a dose of 1.0 mg/kg or 1.5 mg/kg died before
Table I. Serial left ventriculographic and echocardiographic data at baseline, and 1 month and 3 months after
treatment
Hemodynamics
Baseline
(mean 6 SE) 95% CI
1 mo
(mean 6 SE) 95% CI
p Value vs
baseline
3 mo
(mean 6 SE) 95% CI
p Value vs
baseline
p Value vs
1 mo
LVEDV (ml) 27.5 6 1.8 22.8-32.2 38.5 6 1.9 33.7-43.3 0.018 38.3 6 1.9 33.5-43.2 0.015 0.96
LVESV (ml) 7.8 6 1.0 5.3-10.4 23.0 6 2.9 15.6-30.4 0.0009 24.3 6 2.1 19.0-29.6 0.002 0.73
LVEF (%) 71 6 3.3 62.3-79.4 41.0 6 5.0 28.1-53.9 0.0001 36.3 6 5.5 22.2-50.4 0.001 0.48
LVDd (mm) 27.8 6 0.9 25.4-30.3 34.2 6 0.9 31.7-36.6 0.018 35.5 6 0.6 34.1-36.9 0.003 0.08
LVDs (mm) 17.8 6 0.8 15.8-19.9 26.5 6 1.0 24.0-29.0 0.003 27.8 6 0.8 25.7-30.0 0.0009 0.01
%FS (%) 36.5 6 0.8 34.4-38.6 22.7 6 1.1 20.0-25.4 0.0001 21.7 6 1.4 18.1-25.3 0.0003 0.14
IVSd (mm) 9.3 6 0.4 8.2-10.4 7.8 6 0.7 6.2-9.5 0.19 7.5 6 0.3 6.6-8.4 0.06 0.47
PWd (mm) 7.8 6 0.6 6.3-9.4 7.0 6 0.7 5.2-8.8 0.50 6.5 6 0.2 5.9-7.1 0.12 0.36
IVSs (mm) 11.0 6 0.6 9.4-12.6 9.1 6 0.2 8.6-9.6 0.01 8.5 6 0.3 7.8-9.2 0.02 0.19
PWs (mm) 10.1 6 0.3 9.4-10.8 8.9 6 0.3 8.2-9.6 0.0006 8.5 6 0.2 7.9-9.1 0.002 0.06
The values are expressed as mean 6 the standard error (SE) of the mean. The p values are calculated by repeated-measures analysis of variance with the
Scheffe F test. CI, Confidence interval; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; LVEF, left ventricular
ejection fraction; LVDd, left ventricular diastolic dimension; LVDs, left ventricular systolic dimension; %FS, fractional shortening; IVSd and PWd,
end-diastolic wall thickness of interventricular septum and posterior wall; IVSs and PWs, end-systolic wall thickness of interventricular septum and posterior
wall.
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completion of 5 weeks. These results suggest that such
doses may cause acute anthracycline cardiotoxicity char-
acterized by pericarditis, myocarditis, acute left ventricu-
lar failure, and arrhythmias.12
Neurohormonal evaluation. Venous blood samples
were obtained from conscious dogs before catheterization
at baseline and 3 months after the last infusion. Plasma
norepinephrine and dopamine concentrations were mea-
sured by high-performance liquid chromatography.
Plasma renin activity and atrial natriuretic peptide levels
were measured by radioimmunoassay.
Histologic evaluation. At the completion of the study,
dogs were killed and the hearts were fixed in 10%
formalin. Transmural tissue samples from the left ventric-
ular and right ventricular free walls were embedded in
paraffin blocks. Tissue samples 5 mm thick were stained
with hematoxylin and eosin and Masson’s trichrome stain
and then analyzed.
Control protocol. Three beagles served as control ani-
mals. Control dogs were anesthetized in an identical
manner as dogs subjected to heart failure and had five
intracoronary infusions of normal saline solution.
Statistical analysis. All data are presented as the mean
value 6 standard error. Variables were compared by
means of a one-way repeated-measures analysis of vari-
ance to determine the effects of doxorubicin. When the
differences were determined by the one-way repeated-
measures analysis of variance to be significant, the differ-
ences were further analyzed by the Scheffe F test.
Results
All six beagles receiving doxorubicin in a dose of
0.7 mg/kg survived and were available for analysis.
The beagles’ weights did not change significantly
from the baseline values. A pleural effusion devel-
oped in one dog, and pericardial effusions devel-
oped in three dogs.
Hemodynamic findings. Serial echocardio-
graphic and angiographic data are shown in Table I
and cardiac catheterization data are summarized in
Table II. All beagles had normal baseline cardiac
function. During the course of evolving heart fail-
ure, a significant decline in left ventricular contrac-
tility and significant left ventricular dilation were
observed (Fig. 1). The left ventricular diastolic and
systolic dimension and volume increased signifi-
cantly at 1 and 3 months after treatment. The
fractional shortening and left ventricular ejection
fraction decreased significantly. Catheterization re-
vealed that the heart rate, pulmonary capillary
wedge pressure, and left ventricular end-diastolic
pressure increased significantly. Cardiac output and
stroke volume decreased significantly. No significant
changes were observed in hemodynamics, chamber
Table II. Serial cardiac catheterization data at baseline, and 1 month and 3 months after treatment
Hemodynamics
Baseline
(mean 6 SE) 95% CI
1 mo
(mean 6 SE) 95% CI
p Value vs
baseline
3 mo
(mean 6 SE) 95% CI
p Value vs
baseline
p Value vs
1 mo
HR (beats/min) 120 6 5.5 106-134 139 6 3.1 131-147 0.018 145 6 5.3 131-158 0.009 0.14
RAP (mm Hg) 2.7 6 0.7 0.8-4.5 2.8 6 0.4 1.8-3.9 0.82 2.2 6 0.2 1.7-2.6 0.54 0.17
RVP (mm Hg) 36 6 2.9 28.6-43.4 38 6 1.8 33.5-42.9 0.31 36 6 1.9 31.4-40.9 0.94 0.14
RVEDP (mm Hg) 2.3 6 0.4 1.2-3.4 2.8 6 0.3 2.0-3.6 0.46 2.5 6 0.2 1.9-3.1 0.74 0.53
PAP (mm Hg) 34 6 2.8 27.1-41.2 35 6 1.8 30.2-39.5 0.83 36 6 1.9 31.0-41.0 0.54 0.32
PCWP (mm Hg) 5.2 6 0.5 3.9-6.4 11.5 6 0.8 9.5-13.5 0.001 12.5 6 1.3 9.1-15.9 0.005 0.20
LVP (mm Hg) 128 6 5.3 115-142 130 6 7.3 111-149 0.83 135 6 8.1 114-156 0.51 0.09
LVEDP (mm Hg) 8.5 6 0.9 6.0-11.0 13.7 6 1.5 9.9-17.5 0.001 14.5 6 1.1 11.6-17.4 0.0001 0.09
AoP (mm Hg) 127 6 5.2 114-141 120 6 7.2 102-139 0.28 123 6 8.1 102-143 0.49 0.18
CO (L/min) 1.99 6 0.07 1.74-2.24 1.71 6 0.10 1.52-1.90 0.008 1.66 6 0.05 1.53-1.79 0.005 0.14
SV (ml) 16.7 6 0.9 14.4-18.9 12.3 6 0.6 10.9-13.8 0.003 11.5 6 0.4 10.4-12.6 0.001 0.14
The values are expressed as mean 6 the standard error (SE) of the mean. The p values are calculated by repeated-measures analysis of variance with the
Scheffe F test. CI, Confidence interval; HR, heart rate; RAP, right atrial pressure; RVP, right ventricular pressure; RVEDP, right ventricular end-diastolic
pressure; PAP, pulmonary arterial pressure; PCWP, pulmonary artery capillary wedge pressure; LVP, left ventricular pressure; LVEDP, left ventricular
end-diastolic pressure; AoP, aortic pressure; CO, cardiac output; SV, stroke volume.
Table III. Plasma neurohormones at baseline and 3 months after treatment
Neurohormones
Baseline
(mean 6 SE) 95% CI
3 mo
(mean 6 SE) 95% CI
p Value vs
baseline
ANP (pg/ml) 33.8 6 7.0 15.9-51.8 76.5 6 14.8 38.5-114.5 0.012
NA (pg/ml) 114 6 27.4 43.6-184.7 423 6 88.9 193.9-651.1 0.024
DOA (pg/ml) 33.7 6 6.1 18.0-49.3 68.5 6 17.1 24.5-112.5 0.081
PRA (ng/ml/hr) 1.32 6 0.13 0.98-1.65 2.58 6 0.50 1.29-3.87 0.077
The values are expressed as mean 6 the standard error (SE) of the mean. The p values are calculated by repeated-measures analysis of variance with the
Scheffe F test. CI, Confidence interval; ANP, atrial natriuretic peptide; NA, noradrenaline; DOA, dopamine; PRA, plasma renin activity.
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size, and contractility between 1 month and 3
months after the last intracoronary infusion of doxo-
rubicin, except for the left ventricular systolic di-
mension, which increased significantly from 26.5 6
1.0 at 1 month to 27.8 6 0.8 mm at 3 months (p 5
0.01). End-systolic thickness of interventricular sep-
tum and left ventricular posterior wall decreased
significantly. A near significant decrease in end-
diastolic wall thickness was also found.
Neurohormonal findings. The changes of plasma
catecholamines, plasma renin activity, and atrial
natriuretic peptide are shown in Table III. The
plasma norepinephrine concentration and plasma
atrial natriuretic peptide level increased signifi-
cantly. Plasma renin activity and dopamine levels
also increased, but the increase was not significantly
different from baseline.
Histologic findings. Degenerative changes with
loss of myofibrils and cytoplasmic vacuolation were
found predominantly in the left ventricular myocar-
dium (Fig. 2). The amount of interstitium increased,
and interstitial fibrosis was noted. The myocytes
Fig. 1. Echocardiograms demonstrating a dilated left ventricle and depressed myocardial contractility. A,
Before treatment. B, Three months after treatment.
The Journal of Thoracic and
Cardiovascular Surgery
June 1998
1 3 7 0 Toyoda, Okada, Kashem
were regularly arranged without signs of disarray,
and no inflammatory cells were seen.
Control animals. No significant hemodynamic
and neurohormonal effects occurred in the control
animals, and no degenerative changes were ob-
served in the myocardium with intracoronary infu-
sion of saline solution.
Discussion
Experimental heart failure has been induced by a
variety of techniques and in many different species
of animals. However, it is hard to evaluate cardiac
hemodynamics accurately in small animals. No sim-
ple and reliable large animal model of chronic
dilated cardiomyopathy has been established.
Coleman and associates13 first described an experi-
mental model of chronic heart failure in the dog
produced by rapid ventricular pacing. However, this
model is not ideal because a thoracotomy is required
to attach a pacing lead to the left ventricle, and the
heart failure induced by rapid pacing may be revers-
ible after the cessation of pacing. Magid and col-
leagues3 described a model of heart failure caused
by chronic experimental aortic regurgitation in rab-
bits. However, the severity of aortic regurgitation is
difficult to regulate and heart failure takes a long
time to develop. Millner and coworkers9 established
a model of chronic left ventricular failure induced by
ligating the second diagonal coronary artery in
sheep. This method also requires a thoracotomy and
may not induce chronic heart failure in dogs, which
have greater collateral vessels than sheep. Sabbah
and associates14 described a simple and reproduc-
ible canine model of chronic heart failure owing to
myocardial infarction caused by multiple sequential
coronary microembolizations. Their technique re-
quires coronary cannulation without thoracotomy,
as does our method. However, the Sabbah model
represents heart failure caused by myocardial infarc-
tion, in other words, ischemic cardiomyopathy,
which is different from our model of dilated cardio-
myopathy. The mortality rate for their method is
higher than that for our method. This increased
mortality may be caused by myocardial infarction–
induced arrhythmias.
Doxorubicin, anthracycline antibiotics isolated
from cultures of Streptomyces species, is composed
of an anthraquinone chromophore and a 6-carbon
amino sugar joined through a glycosidic linkage and
displays broad activity against human neoplasms.
The clinical value of this compound is limited by the
development of degenerative cardiomyopathy.15 It
has been suggested that doxorubicin causes a dose-
dependent cardiomyopathy and that cardiotoxicity is
related to the peak plasma doxorubicin concentra-
tion.16 Lowering the peak plasma concentration may
reduce the amount of doxorubicin entering myocar-
dial cells.17 Reduction of the peak concentration of
Fig. 2. Microscopic appearance of representative myocardial specimens showing loss of myofibrils with
scattered cytoplasmic vacuolation in the left ventricular myocardium. The interstitial space is increased and
interstitial fibrosis is demonstrated by Masson’s trichrome staining (original magnification 3200).
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doxorubicin decreases cardiotoxicity but does not
diminish myelosuppression, which was related to the
total dose.16 The basis of our method is to deliver
higher peak concentrations of the drug to the myo-
cardial cells, while reducing the total systemic dose.
Proposed mechanisms for doxorubicin cardiotox-
icity include release of superoxides leading to con-
version of membrane unsaturated fatty acids to lipid
peroxides,18 which can inhibit biosynthesis of coen-
zyme Q10 (ubiquinone) and inhibit sodium-potas-
sium adenosinetriphosphatase. In addition, doxoru-
bicin can cause the release of compounds such as
histamine, arachidonic acid metabolites, platelet
activating factor, and calcium, which can cause
myocyte injury.19 Pathologic features of doxorubicin
cardiotoxicity include characteristic vesiculation of
myocardial cells, a loss of subcellular structural
elements, mitochondrial degeneration, loss of myo-
filaments, and progressive atrophy of myofibers.
These myocardial changes are cumulative and po-
tentially nonreversible.20
Heart failure is thought to arise directly from the
loss of functioning myocardium and from many
secondary processes that contribute to the depres-
sion of left ventricular function. Chief among these
is pathologic remodeling, in which dilation and
resultant afterload excess combine to initiate a
downward spiral of deterioration in function, with
subsequent hemodynamic and neurohormonal ad-
aptations to left ventricular dysfunction. In our
model, the depression of left ventricular function is
accompanied by activation of the sympathetic ner-
vous system and by increased secretion of atrial
natriuretic peptide and plasma renin activity. These
findings are consistent with observations made in
patients with heart failure.21
Our findings indicate that chronic heart failure,
characterized by left ventricular dilation, depressed
contractility and increased filling pressure, and by
myocardial damage with loss of myofibrils and cyto-
plasmic vacuolation, can be effectively produced in
dogs by repetitive intracoronary infusions of doxo-
rubicin. These pathologic changes were observed in
the left ventricular free wall and the interventricular
septum, but the right ventricle seemed to be affected
slightly by doxorubicin. Selective infusion of doxo-
rubicin into the left coronary artery induced toxic
effects predominantly in the left ventricle. Previous
attempts to induce heart failure with repeated intra-
venous injections of doxorubicin have been limited
by myelosuppression when the drug is given system-
ically.22, 23 In contrast, the method of Magovern and
associates,10 in which intracoronary doxorubicin was
given in small doses, did not produce significant
systemic toxicity. However, their technique relies on
complex procedures including thoracotomy, pericar-
diotomy, insertion of a catheter into the diagonal
coronary artery of the beating heart, and ligation of
the distal coronary artery. Our method requires only
cannulation of the coronary artery via the femoral
artery and transcatheter infusion of doxorubicin. No
significant systemic side effects occurred with our
method.
In conclusion, our model closely mimics dilated
cardiomyopathy without myocardial ischemia. Five
intracoronary injections of a 0.7 mg/kg dose of
doxorubicin may be a preferable method of inducing
chronic irreversible cardiomyopathy in dogs. This
model should be useful for studying the pathophys-
iology of heart failure and for evaluating the efficacy
of pharmacologic therapies, ventricular repair, car-
diomyoplasty, or heart transplantation in patients
with dilated cardiomyopathy.
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